Clinical Trial Update: Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection [Phase 2]

View source ↗

Summary

Phase 2 trial investigating AT-527 in combination with daclatasvir for hepatitis C virus infection has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• AT-527
• Daclatasvir (daclatasvir)

Snippet

Sponsor: Atea Pharmaceuticals, Inc. | Conditions: Hepatitis C, Hepatitis C, Chronic | Phase 2 | Status: COMPLETED